Apellis Pharmaceuticals, Inc.
APLS
Κατάταξη σε μετοχές
#3328
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Τιμή μετοχής
$41.03
Τελευταίος συγχρονισμός: 2026-05-15
Κεφαλαιοποίηση
$5.25B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
51.57%
Χώρα
US
Εμπόριο Apellis Pharmaceuticals, Inc. (APLS)
Κατηγορία
Healthcare
Αριθμός κυκλοφορούντων μετοχών για Apellis Pharmaceuticals, Inc. (APLS)
Αριθμός κυκλοφορούντων μετοχών στις March 2026: 0.00
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Apellis Pharmaceuticals, Inc., ο τρέχων αριθμός κυκλοφορούντων μετοχών είναι 0.00. Στο τέλος του December 2023, η εταιρεία είχε 118.68M κυκλοφορούντες μετοχές. Ο αριθμός των κυκλοφορούντων μετοχών επηρεάζεται συνήθως από διασπάσεις μετοχών και επαναγορές.
Ιστορικό κυκλοφορούντων μετοχών για Apellis Pharmaceuticals, Inc. (APLS) από 2013 έως 2026
Κυκλοφορούντες μετοχές στο τέλος κάθε έτους
| Έτος | Κυκλοφορούντες μετοχές | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 123.91M | 4.40% |
| 2023 | 118.68M | 11.84% |
| 2022 | 106.11M | 25.70% |
| 2021 | 84.42M | 12.32% |
| 2020 | 75.16M | 20.78% |
| 2019 | 62.23M | 14.40% |
| 2018 | 54.40M | 58.94% |
| 2017 | 34.22M | 89.15% |
| 2016 | 18.09M | 0.00% |
| 2015 | 18.09M | 0.00% |
| 2014 | 18.09M | 294.79% |
| 2013 | 4.58M | 0.00% |
Κυκλοφορούντες μετοχές για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Κυκλοφορούντες μετοχές | Διαφορά | Χώρα |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
